S1900G : Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that has EGFR and MET gene changes.

Capmatinib and osimertinib are in a class of medications called kinase inhibitors. They work by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells and may help shrink tumors. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving capmatinib, osimertinib, and/or ramucirumab and targeting abnormal gene changes in tumor cells may be effective in shrinking or stabilizing advanced non-small cell lung cancer.

Inclusion Criteria

• Diagnosis & Prior Treatment:
  • Participants must have non-small cell lung cancer (NSCLC) with specific genetic features and have already received treatment (such as osimertinib). The cancer must have shown signs of growth or return after treatment.
• Genetic Testing:
  • The cancer must show a specific MET gene change (amplification) confirmed through approved laboratory testing. This testing may come from previous results or new samples collected for the study.
• Study Assignment:
  • Participants must be officially assigned to this study (S1900G) through the LUNGMAP program, which matches patients to research studies based on their tumor’s genetic profile.
• Health & Ability to Participate:
  • Participants must be 18 or older, able to swallow pills, and generally well enough to take part in the study. They must also agree to provide blood and tissue samples for testing and research purposes.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.